REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1460-1468

  Wang, Wenjie ^a,b   Sheng, Wenjiong ^a   Yu, Chenxiao ^a   Cao, Jianping ^a   Zhou, Jundong ^c   Wu, Jinchang ^c   Zhang, Huojun ^d   Zhang, Shuyu ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemosensitivity; Cisplatin; Non small cell lung cancer; REV3L

Indexed keywords

CISPLATIN; DNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN; REV3L PROTEIN; RNA DIRECTED DNA POLYMERASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE ZETA; REV3L PROTEIN, HUMAN;

ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84937207293     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4121     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Langer CJ, Mok T and Postmus PE: Targeted agents in the third-/ fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev 39: 252-260, 2013.
3. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced nonsmall-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074, 2011.
4. O'Rourke N, Roqué I Figuls M, Farré Bernadó N and Macbeth F: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 6: CD002140, 2010.
5. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and O'Byrne KJ: Generation and characterisation of cisplatinresistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193, 2013.
6. Einhorn LH: First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology? J Clin Oncol 26: 3485-3486, 2008.
7. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 30: 1692-1698, 2012.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883, 2012.
9. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
10. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008.
11. Basu A and Krishnamurthy S: Cellular responses to Cisplatininduced DNA damage. J Nucleic Acids 2010: 201367, 2010.
12. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
13. Friedberg EC, Lehmann AR and Fuchs RP: Trading places: How do DNA polymerases switch during translesion DNA synthesis? Mol Cell 18: 499-505, 2005.
14. Gan GN, Wittschieben JP, Wittschieben BO and Wood RD: DNA polymerase zeta (pol zeta) in higher eukaryotes. Cell Res 18: 174-183, 2008.
15. Okada T, Sonoda E, Yoshimura M, Kawano Y, Saya H, Kohzaki M and Takeda S: Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol 25: 6103-6111, 2005.
16. Shen X, Jun S, O'Neal LE, Sonoda E, Bemark M, Sale JE and Li L: REV3 and REV1 play major roles in recombinationindependent repair of DNA interstrand cross-links mediated by monoubiquitinated proliferating cell nuclear antigen (PCNA). J Biol Chem 281: 13869-13872, 2006.
17. Wittschieben JP, Reshmi SC, Gollin SM and Wood RD: Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res 66: 134-142, 2006.
18. Pan Q, Fang Y, Xu Y, Zhang K and Hu X: Down-regulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers. Cancer Lett 217: 139-147, 2005.
19. Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu J, Wu W, Shen H, Wei Q and Lu D: REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene 32: 242-250, 2013.
20. Lin X, Trang J, Okuda T and Howell SB: DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res 12: 563-568, 2006.
21. Eastman A, Jennerwein MM and Nagel DL: Characterization of bifunctional adducts produced in DNA by transdiamminedichloroplatinum( II). Chem Biol Interact 67: 71-80, 1988.
22. Zhang S, Lu J, Zhao X, Wu W, Wang H, Lu J, Wu Q, Chen X, Fan W, Chen H, et al: A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis 31: 1251-1258, 2010.
23. Jamieson ER and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
24. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, Orelli BJ, Bishop DK, Hirano S, Ohzeki M, et al: Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65: 11704-11711, 2005.
25. Lange SS, Takata K and Wood RD: DNA polymerases and cancer. Nat Rev Cancer 11: 96-110, 2011.
26. Albertella MR, Green CM, Lehmann AR and O'Connor MJ: A role for polymerase eta in the cellular tolerance to cisplatininduced damage. Cancer Res 65: 9799-9806, 2005.
27. Alt A, Lammens K, Chiocchini C, Lammens A, Pieck JC, Kuch D, Hopfner KP and Carell T: Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. Science 318: 967-970, 2007.
28. Wu F, Lin X, Okuda T and Howell SB: DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res 64: 8029-8035, 2004.
29. Okuda T, Lin X, Trang J and Howell SB: Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol 67: 1852-1860, 2005.
30. Lin X, Okuda T, Trang J and Howell SB: Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 69: 1748-1754, 2006.
31. Cheung HW, Chun AC, Wang Q, Deng W, Hu L, Guan XY, Nicholls JM, Ling MT, Chuan Wong Y, Tsao SW, et al: Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res 66: 4357-4367, 2006.
32. Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z, Yang J, et al: REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy. Neuro-oncol 11: 790-802, 2009.
33. Tan NY and Khachigian LM: Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 29: 2483-2488, 2009.
34. Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J and Mudryj M: Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 20: 5737-5747, 2001.
35. Iwahori S, Yasui Y, Kudoh A, Sato Y, Nakayama S, Murata T, Isomura H and Tsurumi T: Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal 20: 1795-1803, 2008.
36. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R and Ratan RR: Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 23: 3597-3606, 2003.
37. Meighan-Mantha RL, Riegel AT, Suy S, Harris V, Wang FH, Lozano C, Whiteside TL and Kasid U: Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. Mol Cell Biochem 199: 209-215, 1999.
38. Grande L, Bretones G, Rosa-Garrido M, Garrido-Martin EM, Hernandez T, Fraile S, Botella L, de Alava E, Vidal A, Garcia del Muro X, et al: Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem 287: 26495-26505, 2012.